PMID- 24456080
OWN - NLM
STAT- MEDLINE
DCOM- 20141218
LR  - 20140319
IS  - 1744-7674 (Electronic)
IS  - 1354-3776 (Linking)
VI  - 24
IP  - 4
DP  - 2014 Apr
TI  - Retinoid X receptor ligands: a patent review (2007 - 2013).
PG  - 443-52
LID - 10.1517/13543776.2014.880692 [doi]
AB  - INTRODUCTION: Retinoid X receptors (RXRs) are nuclear receptors that act as 
      ligand-dependent transcription factors. RXRs function as homodimers or as 
      heterodimers with other nuclear receptors, such as retinoic acid receptors, 
      PPARs, liver X receptors, farnesoid X receptor, vitamin D receptor or thyroid 
      hormone receptors. RXR ligands (agonists or antagonists) show various 
      physiological effects, depending on their partner receptors. RXR agonist 
      bexarotene (Targretin(R)) is used for the treatment of cutaneous T-cell lymphoma in 
      clinical practice. RXR agonists were also reported to be useful for treatment of 
      type 2 diabetes, autoimmune disease and Alzheimer's disease. RXR antagonists were 
      also reported to be effective in type 2 diabetes treatment. AREAS COVERED: Here 
      patent applications (2007 - 2013) concerning RXR ligands are summarized, and the 
      usefulness of RXR ligands as pharmaceutical agents is discussed. EXPERT OPINION: 
      RXR agonists show a wide variety of biological effects. However, they cause 
      serious side effects, such as blood triglyceride elevation, hypothyroidism and 
      others. Thus, for clinical application of RXR agonists, abrogation of these side 
      effects is required. RXR heterodimer-selective agonists and RXR partial agonists 
      exhibiting desired effects without side effects are expected to find clinical 
      application.
FAU - Yamada, Shoya
AU  - Yamada S
AD  - Okayama University Graduate School of Medicine, Division of Pharmaceutical 
      Sciences, Dentistry and Pharmaceutical Sciences , 1-1-1, Tsushima-Naka, Kita-Ku, 
      Okayama 700-8530 , Japan +81 086 251 7963 ; +81 086 251 7963 ; 
      kakuta-h@cc.okayama-u.ac.jp.
FAU - Kakuta, Hiroki
AU  - Kakuta H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140124
PL  - England
TA  - Expert Opin Ther Pat
JT  - Expert opinion on therapeutic patents
JID - 9516419
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Ligands)
RN  - 0 (Retinoid X Receptors)
SB  - IM
MH  - Alzheimer Disease/drug therapy
MH  - Animals
MH  - Antineoplastic Agents/therapeutic use
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - Drug Discovery
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Hypolipidemic Agents/therapeutic use
MH  - Ligands
MH  - Medicine, Chinese Traditional
MH  - *Patents as Topic
MH  - Protein Multimerization
MH  - Retinoid X Receptors/*agonists/chemistry
EDAT- 2014/01/25 06:00
MHDA- 2014/12/19 06:00
CRDT- 2014/01/25 06:00
PHST- 2014/01/25 06:00 [entrez]
PHST- 2014/01/25 06:00 [pubmed]
PHST- 2014/12/19 06:00 [medline]
AID - 10.1517/13543776.2014.880692 [doi]
PST - ppublish
SO  - Expert Opin Ther Pat. 2014 Apr;24(4):443-52. doi: 10.1517/13543776.2014.880692. 
      Epub 2014 Jan 24.